JeniVision

This biopharmaceutical company develops ophthalmology therapies delivered through a non-invasive ocular pathway for high bioavailability in the retina. Their technology aims to prevent the development of blinding wet age-related macular degeneration (AMD).

Updated 2 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Founder details are not available yet.

Product

Problem

Current treatments for retinal diseases like glaucoma, dry eye, retinopathy of prematurity (ROP), myopia and age-related macular degeneration (AMD) often involve invasive procedures and may not effectively deliver drugs to the retina, limiting bioavailability and therapeutic efficacy. This can lead to suboptimal outcomes and increased burden for patients requiring frequent interventions.

Solution

JeniVision is developing ophthalmology therapies utilizing a proprietary non-invasive ocular delivery pathway (NIODP) designed to enhance drug delivery to the retina with high bioavailability. Their approach aims to treat and prevent common vision loss diseases, including glaucoma, dry eye, ROP, myopia, and both dry and wet AMD. By delivering medication non-invasively, JeniVision seeks to improve patient outcomes and reduce the need for more invasive procedures. The company has candidates in preclinical and clinical stages.

Target Audience

The primary target audience includes patients at risk of or affected by retinal diseases such as glaucoma, dry eye, ROP, myopia, and AMD, as well as ophthalmologists and other eye care professionals seeking innovative treatment options.

Features

Non-invasive ocular delivery pathway (NIODP) for targeted drug delivery to the retina.
Focus on therapies for glaucoma, dry eye, ROP, myopia, and AMD.
Drug candidates in preclinical and clinical stages of development.
Designed for high bioavailability of therapeutics in the retina.